A Phase 1 Trial of Intravenous Boronophenylalanine-Fructose Complex in Patients with Glioblastoma Multiforme

  • R. Bergland
  • E. Elowitz
  • J. A. Coderre
  • D. Joel
  • M. Chadha


Seven patients with glioblastoma multiforme received 2-hour intravenous infusions of p-boronophenylalanine (BPA) prior to craniotomy. The BPA was solubilized for injection by complexation with fructose. Administered BPA doses were 100mg BPA/kg (n=1), 130 mg BPA/kg (n=5) and 170 mg BPA/kg (n=1). The boron concentration in blood was proportional to the administered dose. The boron concentrations in scalp were 1-2 times higher than the corresponding boron concentration in the blood. The boron concentrations in the tumor (range, 11–26µg 10B/g) were from 1–4 times the corresponding levels in the blood.


Boron Concentration Biodistribution Study Boron Neutron Capture Therapy Brookhaven National Laboratory Prompt Gamma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    L.E. Farr, W.H. Sweet, J.S. Robertson, C.G. Foster, H.B. Locksley, D.L. Suntherland, M.L. Mendelsohn and E.E. Stickly, Neutron capture therapy with boron in the treatment of glioblastoma multiforme. Am. J. Roentgenol. 71: 279–291, 1954.Google Scholar
  2. 2.
    H. Hatanaka and Y. Nakagawa, Clinical results of long-surviving brain tumor patients who underwent boron neutron capture therapy. Int. J. Radiat. Oncol. Biol. Phys. 28: 1061–1066, 1994.PubMedCrossRefGoogle Scholar
  3. 3.
    Y. Mishima, C. Honda, M. Ichihashi, H. Obara, J. Hiratsuka, H. Fukuda, H. Karashima, T. Kobayashi, K. Kanda and K. Yoshino, Treatment of malignant melanoma by single thermal neutron capture therapy with melanoma-seeking IOB compound. Lancet 12: 388–389, 1989.CrossRefGoogle Scholar
  4. 4.
    Y. Mishima, M. lchihashi, C. Honda, M. Shiono, T. Nakagawa, H. Obara, J. Shirakawa, J. Hiratsuka, K. Kanda, T. Kobayashi, T. Nozaki, O. Aigawa, T. Sato, H. Karashima, K. Yoshino and H. Fukuda, Advances in the control of cutaneous primary and metastatic melanoma by thermal neutron capture therapy. in: “Progress in Neutron Capture Therapy for Cancer,” B. Allen, D. Moore and B. Harrington, ed., Plenum Press, New York, 1992, pp 577–583.CrossRefGoogle Scholar
  5. 5.
    H. Fukuda, J. Hiratsuka, C. Honda, T. Kobayashi, K. Yoshino, H. Karashima. J. Takahashi, Y. Abe, K. Kanda, M. Ichihashi and Y. Mishima, Boron neutron capture therapy of malignant melanoma using 10B-paraboronophenylalanine with special reference to evaluation of radiation dose and damage to the normal skin. Radiat. Res. 138: 435–442, 1994.PubMedCrossRefGoogle Scholar
  6. 6.
    J.A. Coderre, D.D. Joel, P.L. Micca, M.M. Nawrocky and D.N. Slatkin, Control of intracerebral gliosarcoma in rats by boron neutron capture therapy with p-boronophenylalanine. Radiat. Res. 129: 290296, 1992.Google Scholar
  7. 7.
    K. Yoshino, A. Suzuki, Y. Mori, H. Kanihana, C. Honda, Y. Mishima, T. Kobayashi and K. Kanda, Improvement of solubility of p-boronophenylalanine by complex formation with monosaccharides. Strahlentherapie und Oncologie 165: 127–129, 1989.Google Scholar
  8. 8.
    T. Lahann, D. Lu, C. Sills, G, Daniell, S. Kraft, P. Gavina and W. Bauer, Bioavailability of intravenous formulations of p-boronophenylalanine. in: “Advances in Neutron Capture Therapy,” A. Soloway, R. Barth and D. Carpenter, ed., Plenum Press, New York, 1993, pp 513–517.CrossRefGoogle Scholar
  9. 9.
    R. Fairchild, D. Gabel, B. Laster, D. Greenberg, W. Kiszenick and P. Micca, Microanalytical techniques for boron analysis using the lOB(n,a)7Li reaction. Med. Phys. 13: 50–56, 1986.PubMedCrossRefGoogle Scholar
  10. 10.
    Y. Mishima, M. Ichihashi and T. Nakanishi, Cure of malignant melanoma by single thermal neutron capture treatment using melanoma seeking compounds: l OB/melanogenesis interaction to in vitro/in vivo radiobiological analysis to preclinical studies. in: “Proceedings of the First International Symposium on Neutron Capture Therapy,” R. Fairchild and G. Brownell, ed., Brookhaven National Laboratory, Upton, 1983, pp 355–364.Google Scholar
  11. 11.
    J. Coderre, J. Glass, R. Fairchild, P. Micca, I. Fand and D. Joel, Selective delivery of boron by the melanin precursor analog p-boronophenylalanine to tumors other than melanoma. Cancer Res. 50: 138–141, 1990.PubMedGoogle Scholar
  12. 12.
    J. Coderre, M. Makar, P. Micca, M. Nawrocky, H. Liu, D. Joel, D. Slatkin and H. Amols, Derivations of relative biological effectiveness for the high-LET radiations produced during boron neutron capture irradiations of the 9L rat gliosarcoma in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 27: 1121–1129, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Y. Mori, A. Suzuki, K. Yoshino and H. Kanihana, Complex formation of p-boronophenylalanine with some monosaccharides. Pigment Cell Research 2: 273–277, 1989.PubMedCrossRefGoogle Scholar
  14. 14.
    J. Coderre, A phase 1 biodistribution study of p-boronophenylalanine. in: “Boron Neutron Capture Therapy: Towards Clinical Trials of Glioma with BNCT,” R. Moss and D. Gabel, ed.,. Plenum Press, New York, 1992, pp 111–121.Google Scholar
  15. 15.
    J. Mallesch, D. Moore, B. Allen, W. McCarthy, R. Jones and W. Stening, The pharmacokinetics of p-boronophenylalanine-fructose in human patients with glioma and metastatic melanoma. Int. J. Radiat. Oncol. Biol. Phys. 28: 1183–1188, 1994.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • R. Bergland
    • 1
  • E. Elowitz
    • 1
  • J. A. Coderre
    • 2
  • D. Joel
    • 2
  • M. Chadha
    • 3
  1. 1.Departments of NeurosurgeryBeth Israel Medical CenterNew YorkUSA
  2. 2.Medical DepartmentBrookhaven National LaboratoryUptonUSA
  3. 3.Radiation OncologyBeth Israel Medical CenterNew YorkUSA

Personalised recommendations